IN2012DN00239A - - Google Patents

Info

Publication number
IN2012DN00239A
IN2012DN00239A IN239DEN2012A IN2012DN00239A IN 2012DN00239 A IN2012DN00239 A IN 2012DN00239A IN 239DEN2012 A IN239DEN2012 A IN 239DEN2012A IN 2012DN00239 A IN2012DN00239 A IN 2012DN00239A
Authority
IN
India
Prior art keywords
compositions
morpholin
trifluoromethoxy
pyridin
biphenyl
Prior art date
Application number
Inventor
Andreas Fritze
Karine Corcelle
Melinda Eniko Grubesa
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2012DN00239A publication Critical patent/IN2012DN00239A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to topical pharmaceutical compositions of 2 -Methyl - 41 -trifluoromethoxy-biphenyl -3 - carboxylic acid [6 -(cis - 2, 6 - dimethyl -morpholin - 4 -yl) -pyridin - 3 -yl] - amide, to the use of such compositions in therapeutic applications and to methods for manufacturing such compositions.
IN239DEN2012 2009-07-21 2010-07-20 IN2012DN00239A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22714109P 2009-07-21 2009-07-21
US29588410P 2010-01-18 2010-01-18
PCT/EP2010/060470 WO2011009852A2 (en) 2009-07-21 2010-07-20 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
IN2012DN00239A true IN2012DN00239A (en) 2015-05-01

Family

ID=42633096

Family Applications (1)

Application Number Title Priority Date Filing Date
IN239DEN2012 IN2012DN00239A (en) 2009-07-21 2010-07-20

Country Status (16)

Country Link
US (1) US8722672B2 (en)
EP (1) EP2456422B1 (en)
JP (2) JP6106434B2 (en)
KR (1) KR101732751B1 (en)
CN (2) CN103893184B (en)
AR (1) AR077490A1 (en)
AU (1) AU2010275240A1 (en)
BR (1) BR112012001340B1 (en)
CA (1) CA2768457C (en)
ES (1) ES2576740T3 (en)
HK (1) HK1199217A1 (en)
IN (1) IN2012DN00239A (en)
MX (1) MX2012000954A (en)
RU (1) RU2589699C2 (en)
TW (1) TW201107314A (en)
WO (1) WO2011009852A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (en) 2006-12-28 2014-04-11 Infinity Discovery Inc Cyclopamine analogs
CA2837852A1 (en) * 2011-06-02 2012-12-06 Novartis Ag Biomarkers for hedgehog inhibitor therapy
CO6910042A1 (en) 2011-09-28 2014-03-31 Titan Wood Ltd Medium density fiber panels
WO2014128661A1 (en) * 2013-02-25 2014-08-28 Novartis Ag Oral formulation and suspension of an oncology drug
CN105906616B (en) * 2015-03-30 2018-09-04 苏州晶云药物科技有限公司 The crystal form and preparation method thereof of LDE225 monophosphates
HK1253345A1 (en) 2015-06-04 2019-06-14 Pellepharm Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
CN105330658B (en) * 2015-12-09 2017-09-19 苏州明锐医药科技有限公司 Preparation method of sonjib
CN112773805B (en) * 2019-11-11 2024-05-10 中国科学院脑科学与智能技术卓越创新中心 Novel therapeutic agent for ischemic brain injury

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082881A (en) * 1976-12-23 1978-04-04 E. R. Squibb & Sons, Inc. Topical and other type pharmaceutical formulations containing isosorbide carrier
US5216011A (en) * 1989-09-01 1993-06-01 Bristol-Myers Squibb Co. Stable solutions of mitomycin c
IT1265001B1 (en) * 1993-12-16 1996-10-17 Zambon Spa PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING (S) -2- (4- ISOBUTYLPHENYL) PROPIONIC ACID
DE4405898A1 (en) * 1994-02-18 1995-08-24 Schering Ag Transdermal therapeutic systems containing sex steroids
FR2719475B1 (en) * 1994-05-05 1996-06-07 Oreal Cosmetic and / or dermatological composition with cationic polymeric gelling agent, its uses in particular for depigmentation of the skin.
US6765001B2 (en) * 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
RU2207124C1 (en) * 2002-04-24 2003-06-27 Закрытое акционерное общество "Брынцалов-А" Cream "bramizil" with antifungal effect
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
DE102006014454B3 (en) 2006-03-29 2007-11-08 Hoffmann, Frank Punching device with feeding device
UA93548C2 (en) 2006-05-05 2011-02-25 Айерем Елелсі Compounds and compositions as hedgehog pathway modulators
ES2569941T3 (en) 2007-06-07 2016-05-13 Novartis Ag Biphenylcarboxamide derivatives as hedgehog path modulators
CN101445508B (en) 2008-11-21 2011-08-31 南京威尔化工有限公司 Method for synthesizing isosorbide dimethyl ether

Also Published As

Publication number Publication date
ES2576740T3 (en) 2016-07-11
US20120122866A1 (en) 2012-05-17
CA2768457A1 (en) 2011-01-27
EP2456422B1 (en) 2016-03-16
EP2456422A2 (en) 2012-05-30
BR112012001340B1 (en) 2021-08-03
AR077490A1 (en) 2011-08-31
CN103893184A (en) 2014-07-02
JP6106434B2 (en) 2017-03-29
US8722672B2 (en) 2014-05-13
BR112012001340A2 (en) 2016-03-15
RU2589699C2 (en) 2016-07-10
HK1199217A1 (en) 2015-06-26
AU2010275240A1 (en) 2012-02-02
MX2012000954A (en) 2012-02-28
KR101732751B1 (en) 2017-05-04
CA2768457C (en) 2018-01-23
KR20120097482A (en) 2012-09-04
CN102481249A (en) 2012-05-30
WO2011009852A2 (en) 2011-01-27
RU2012105752A (en) 2013-08-27
WO2011009852A3 (en) 2012-01-19
JP2012533598A (en) 2012-12-27
TW201107314A (en) 2011-03-01
CN103893184B (en) 2016-03-02
JP2015199753A (en) 2015-11-12

Similar Documents

Publication Publication Date Title
PH12015500274A1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
IN2012DN00239A (en)
TN2012000549A1 (en) Substituted 5-fluoro-1h-pyrazolopyridines and use thereof
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
MY191669A (en) Pyrazolyl quinoxaline kinase inihibitors
CA2818187C (en) Bromodomain inhibitors and uses thereof
EA020330B3 (en) Quinazoline compounds
UA105290C2 (en) APTAMERS TO β-NGF AND THEIR USE IN TREATING β-NGF MEDIATED DISEASES AND DISORDERS
MY188960A (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
IN2012DN03312A (en)
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
MX360598B (en) Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof.
GB201106743D0 (en) Novel compounds
TN2012000457A1 (en) Fe(iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias
DK3045456T3 (en) BICYCLICALLY SUBSTITUTED URACILES AND APPLICATION
WO2011141685A3 (en) Systemic nasal compositions comprising cocoyl proline or at least one of the constituents thereof
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
NZ719185A (en) Crystalline forms of therapeutic compounds and uses thereof
MX2013004759A (en) Oxime compounds as hdl-cholesterol raising agents.
WO2012019428A8 (en) Benzohydrol derivatives, a preparation process and pharmaceutical use thereof
IN2014DN09437A (en)
ATE524488T1 (en) LYSOBACTINAMIDE
MX2013002261A (en) Substituted n-phenethyltriazoloneacetamides and use thereof.
MY168952A (en) Fe (iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias
TN2011000588A1 (en) Novel pharmaceutically acceptable salts of 4-(1h-imidazol-4-ylmethyl) pyridine and their therapeutical uses